Evotec SE (MIL:1EVT)
€ 8.345 0 (0%) Market Cap: 1.52 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 1.56 GF Score: 54/100

Q3 2022 Evotec SE Earnings Call Transcript

Nov 09, 2022 / 01:00PM GMT
Werner Lanthaler
Evotec SE - Chairman of Management Board & CEO

Good morning, good afternoon. Welcome from Evotec. Welcome to our Q9 presentation for Together for medicines that matter.

We have uploaded the presentation that is accompanying this call to our website, and you can follow this call throughout the next couple of quarters. When you go to Page 2 of this presentation. You can see that I'm here together with my team, our CFO, Enno; our COO, Craig; our CSO, Cord; and our CBO, Matthias. Enno and I will guide you through the initial report, and then we are all looking forward to your questions and are happy to answer them.

As you know, this call follows our second Capital Markets Day of 2022, which we had last week in Redmond and which was focused more or less only on Just-Evotec Biologics. So we are very happy to today give you a broader picture about the whole business ongoing in the group. And we will also, at this point of time, of course, refer to Just-Evotec Biologics. But if you have more detailed questions to Just, let me please also advise you to go to the Internet

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot